SR 4233 (Tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours

British Journal of Cancer

Volumn 67, Issue 6, 1993, Pages 1163-1170

  Brown, J M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETANIDAZOLE; HYDRALAZINE; MELPHALAN; MITOMYCIN C; NITROIMIDAZOLE DERIVATIVE; TIRAPAZAMINE;

BONE MARROW TOXICITY; CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; HUMAN; HYPOXIA; HYPOXIC CELL; MAMMAL CELL; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; OXYGEN CONCENTRATION; OXYGEN TENSION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TARGET CELL; TUMOR CELL DESTRUCTION;

ANIMAL; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMAN; MICE; NEOPLASMS, EXPERIMENTAL; SUPPORT, U.S. GOV'T, P.H.S.; TRIAZINES;

EID: 0027288316     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1993.220     Document Type: Article

References (72)

1. ADAMS, G.E. (1981). Hypoxia-mediated drugs for radiation and chemotherapy. Cancer, 48, 696-707.
2. ADAMS, G.E., STRATFORD, I.J., EDWARDS, H.S., BREMNER, J.C.M. & COLES, S. (1992). Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue E09. Int. J. Radiat. Oncol. Biol. Phys., 22, 717-720.
3. BAKER, M.A., ZEMAN, E.M., HIRST, V.K. & BROWN, J.M. (1988). Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res., 48, 5947-5952.
4. BEDFORD, J.S. & GOODHEAD, D.T. (1989). Breakage of human interphase chromosomes by a particles and X-rays. Int. J. Radiat. Biol., 55, 211-216.
5. BIEDERMANN, K.A., WANG, J., GRAHAM, R.P. & BROWN, J.M. (1991). SR4233 cytotoxicity and metabolism in DNA repair- competent and repair-deficient cell cultures. Br. J. Cancer, 63, 358-362.
6. BREMNER, J.C.M., STRATFORD, I.J., BOWLER, J. & ADAMS, G.E. (1990). Bioreductive drugs and the selective induction of tumour hypoxia. Br. J. Cancer, 61, 717-721.
7. BROWN, J.M. (1987). Exploitation of bioreductive agents with vasoactive drugs. In Radiation Research: Proceedings of the 8th International Congress of Radiation Research, Fielden, E.M., Fowler, J.F., Hendry, J.H. & Scott, D. (eds). pp. 719-724. Taylor & Francis: London.
8. BROWN, J.M. (1989). Hypoxic cell radiosensitizers. Where next? Int. J. Radiat. Oncol. Biol. Phys., 16, 987-993.
9. BROWN, J.M. (1991). Redox activation of benzotriazine N-oxides: mechanisms and potential as anticancer drugs. In Selective Activation of Drugs by Redox Processes, Breccia, A., Adams, G.E., Fielden, E.M. & Wardman, P. (eds). pp. 137-148. Plenum Press: Fermo, Italy.
10. BROWN, J.M. & KOONG, A. (1991). Therapeutic advantage of hypoxic cells in tumors: a theoretical study. JNCI, 83, 178-185.
11. BROWN, J.M. & LEMMON, M.J. (1990). Potentation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50, 7745-7749.
12. BROWN, J.M. & LEMMON, M.J. (1991a). SR4233: a tumor specific radiosensitizer active in fractionated radiation regimens. Radio- ther. & Oncol., 20, 151-156.
13. BROWN, J.M. & LEMMON, M.J. (1991a). Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., 20, 457-461.
14. BROWN, J.M. & LEMMON, M.J. (1992). Fractionation increases the antitumor effect of adding a hypoxic cytotoxin to irradiation. In Radiation Research a Twentieth Century Perspective, Volume II, Dewey, W.C., Edington, M., Fry, R.J.M., Hall, E.J. & Whitmore, G.F. (eds). pp. 807-812. Academic Press: San Diego.
15. BUSH, R.S., JENKIN, R.D.T., ALLT, W.E.C., BEALE, F.A., BEAN, H., DENBO, A.J. & PRINGLE, J.F. (1978). Definite evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer, 37, Suppl. Ill, 302-306.
16. CAHILL, A. & WHITE, I.N.H. (1990). Reductive metabolism of 3- amino-1, 2, 4-benzotriazine-1, 4-dioxide (SR4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinog., 11, 1407-1411.
17. CATER, D.B., GRIGSON, C.M.B. & WATKINSON, D A. (1962). Changes of oxygen tension in tumors induced by vasoconstrictor and vasodilator drugs. Acta Radiol., 58, 401-408.
18. CHAPLIN, D.J. & ACKER, B. (1987). The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int. J. Radiat. Oncol. Biol. Phys., 13, 579-585.
19. CHAPLIN, D.J., HORSMAN, M.R. & AOKI, D.S. (1991). Nicotinamide, Fluosol DNA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br. J. Cancer, 63, 109-113.
20. CORNFORTH, M.N. & BEDFORD, J.S. (1987). A quantitative comparison of potentially lethal damage repair and the rejoining of interphase chromosome breaks in low passage normal human fibroblasts. Radiat. Res., Ill, 385-405.
21. COSTA, A.K., BAKER, M.A., BROWN, J.M. & TRUDELL, J R. (1989). In vitro hepatotoxicity of SR4233 (3-amino-1, 2, 4-benzotriazine-dioxide), a hypoxic cytotoxin and potential antitumor agent. Cancer Res., 49, 925-929.
22. FRACASSO, P.M. & SARTORELLI, A.C. (1986). Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res., 46, 3939-3944.
23. GATENBY, R.A., KESSLER, H.B., ROSENBLUM, J.S., COIA, L.R., MOLDOFSKY, P.J., HARTZ, W.H. & BRODER, G.J. (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 14, 831-838.
24. HENK, J.M. & SMITH, C.W. (1977). Radiotherapy and hyperbaric oxygen in head and neck cancer: interim report of second clinical trial. Lancet, 2, 104.
25. 2 tension measurements. Cancer Res., 51, 6098-6102.
26. HOLDEN, S.A., TEICHER, B.A., ARA, G., HERMAN, T.S. & COLEMAN, C.N. (1992). Enhancement of alkylating agent activity of SR-4233 in the FSallC murine fibrosarcoma. JNCI, 84, 187-193.
27. JENKINS, T.C., NAYLOR, M.A., O’NEILL, P., THREADGILL, M.D., COLE, S., STRATFORD, I.J., ADAMS, G.E., FIELDEN, E.M., SUTO, M.J. & STIER, M.A. (1990). Synthesis and evaluation of: a[(2- Haloethyl)amino]methyl]-2-nitro-l -imidazole- 1-ethanols as Prodrugs of a[(l-Aziridinyl)methyl]-2-nitro-l H-imidazole-1 -ethanol (RSU 1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J. Med. Chem., 33, 2603-2610.
28. KENNEDY, K.A. (1987). Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des., 2, 181-194.
29. KEOHANE, A., GODDEN, J., STRATFORD, I.J. & ADAMS, G.E. (1990). The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation. Br. J. Cancer, 61, 722-726.
30. KIM, I.L. & BROWN, J.M. (1993). Reoxygenation and rehypoxiation in the SCCVII mouse tumor, 41st Annual Meeting of Radiation Research Society, Dallas, TX, March 19-25 (Abstr. p.31-21).
31. KJELLEN, E., JOINER, M.C., COLLIER, J.M., JOHNS, H. & ROJAS, A. (1991). A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. & Oncol., 22, 81-91.
32. KOCH, C.J. (1984). A thin-film culturing technique allowing rapid gas-liquid equilibration (6 sec) with no toxicity to mammalian cells. Radiat. Res., 97, 434-442.
33. KOCH, C.J. (1990). A reductive activation of nitroimidazoles: modification by oxygen and other redox active molecules in cellular systems. In Selective Activation of Drugs by Redox Processes, Breccia, A., Adams, G.E., Fielden, E.M. & Wardman, P. (eds), pp. 237-247. Plenum Press: Fermo, Italy.
34. KOCH, C.J. (1991). Polarographic oxygen sensor. U.S. Patent 5030036. July, 1991.
35. KOCH, C.J. (1993). The unusual dependence on oxygen concentration of toxicity by SR4233 [3-amino-1, 2, 4-benzotriazine 1, 4-dioxide]: an hypoxic cell toxin. Cancer Res. (submitted).
36. LADEROUTE, K., WARDMAN, P. & RAUTH, A.M. (1988). Molecular mechanisms for the hypoxia-dependent activation of 3-amino- benzotriazine 1, 4-dioxide (SR4233). Biochem. Pharmacol., 37, 1487-1495.
37. LIN, A.J., COSBY, L A. & SARTORELLI, A.C. (1976). Potential bioreductive alkylating agents. In Cancer Chemotherapy, Sartorelli, A.C. (ed.), pp. 71-86. American Chemical Society: Washington.
38. LIN, A.J., COSBY, L.A., SHANSKY, C.W. & SARTORELLI, A.C. (1972). Potential bioreductive alkyalting agents. 1. Benzoquinone derivatives. J. Med. Chem., 15, 1247-1252.
39. LLOYD, R.V., DULING, D R., RUMYANTSEVA, G.V., MASON, R.P. & BRIDSON, P.K. (1991). Microsomal reduction of 3-amino-1, 2, 4- benzotriazine 1, 4-dioxide to a free radical. Mol. Pharmacol., 40, 440-445.
40. MARSHALL, R.S. & RAUTH, A.M. (1986). Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant. Cancer Res., 46, 2709-2713.
41. MOORE, H.W. (1977). Bioactiviation as a model for drug design bioreductive alkylation. Science, 197, 527-532.
42. MOULDER, J.E. & ROCKWELL, S. (1987). Tumor hypoxia: its impact on cancer therapy. Cancer Metast. Rev., 5, 313-341.
43. MUELLER-KLIESER, W., VAUPEL, P., MANZ, R. & SCHMIDSEDER, R. (1981). Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int. J. Radiat. One. Biol. Phys., 7, 1397-1404.
44. MULCAHY, R.T. (1984). Effect of oxygen on misonidazole chemosen- sitization and cytotoxicity in vitro. Cancer Res., 44, 4409-4413.
45. OVERGAARD, J., HANSEN, H.S., JORGENSEN, K. & HANSEN, M.H. (1986). Primary radiotherapy of larynx and pharynx carcinomas - an analysis of some factors influencing local control and survival. Int. J. Radiat. One. Biol. Phys., 12, 515-521.
46. 238Pu a-particles. Int. J. Radiat. Biol., 52, 893-902.
47. REVELL, S.H. (1983). Relationship between chromosome damage and cell death. In Radiation-Induced Chromosome Damage in Man, Ishihara, T. & Sasaki, M.S. (eds), pp. 215-233. Alan R. Liss, Inc.: New York, NY.
48. ROCKWELL, S. & KENNEDY, K.A. (1979). Combination therapy with radiation and mitomycin C: preliminary results with EMT6 tumor cells in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys., 5, 1673-1676.
49. ROCKWELL, S., KENNEDY, K.A. & SARTORELLI, A.C. (1982). Mito- mycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity. Int. J. Radiat. Oncol. Biol. Phys., 8, 753-755.
50. ROCKWELL, S. & MOULDER, J.E. (1990). Hypoxic fractions of human tumors xenografted into mice: a review. Int. J. Radiat. One. Biol. Phys., 19, 197-202.
51. ROIZIN-TOWLE, L., PIRRO, J.P. & HALL, E.J. (1990). Studies with bifunctional bioreductive drugs II. Cytotoxicity assayed with A- 549 lung carcinoma cells of human origin. Radiat. Res., 124, S50-S55.
52. SARTORELLI, A.C. (1988). Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res., 48, 775-778.
53. SIEMANN, D.W. (1984). Modification of chemotherapy by nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys., 10, 1585-1594.
54. SPIEGEL, J.F., SPEAR, M.A. & BROWN, J.M. (1993). Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075). Radiotherapy & Oncol., 26, 79-81.
55. STRATFORD, I.J. & STEPHENS, M.A. (1989). The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys., 16, 973-976.
56. STRATFORD, I.J., O’NEILL, P., SHELDON, P.W., SILVER, A.R.J., WALLING, J.M. & ADAMS, G.E. (1986). RSU 1069, A nitroimidazole containing an aziridine group - bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem. Pharm., 35, 105-109.
57. SUN, J.R. & BROWN, J.M. (1989). Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR4233 in a murine carcinoma. Cancer Res., 49, 5664-5670.
58. TANNOCK, I. & GUTTMAN, P. (1981). Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br. J. Cancer, 42, 245-248.
59. TANNOCK, I.F. (1980). In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. Br. J. Cancer, 42, 861-870.
60. TAYLOR, Y.C., EVANS, J.W. & BROWN, J.M. (1983). Mechanism of sensitization of Chinese hamster ovary cells to melphalan by hypoxic treatment with misonidazole. Cancer Res., 43, 3175–3181.
61. TAYLOR, Y.C. & RAUTH, A.M. (1978). Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res., 38, 2745-2752.
62. VAUPEL, P., SCHLENGER, K., KNOOP, C. & HOCKEL, M. (1991). Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized 02 tension measurements. Cancer Res., 51, 3316-3322.
63. VOORHEES, W.D. Ill & BABBS, C.F. (1982). Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur. J. Cancer Clin. Oncol., 18, 1027-1033.
64. WALTON, M.I., WOLF, C.R. & WORKMAN, P. (1992). The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cyto- toxin 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide (SR4233, WIN 59075) by mouse liver. Biochem. Pharmacol., 44, 251-259.
65. WALTON, M.I. & WORKMAN, P. (1990). Enzymology of the reductive bioactivation of SR 4233. Biochem. Pharmacol., 39, 1735-1742.
66. WANG, J., BIEDERMANN, K.A. & BROWN, J.M. (1992). Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res., 52, 4473-4477.
67. WANG, J., BIEDERMANN, K.A., WOLF, C.R. & BROWN, J.M. (1993). Metabolism of the bioreductive cytotoxin SR 4233 by tumor cells: enzymatic studies. Br. J. Cancer, 67, 321-325.
68. WEISSBERG, J.B., SON, Y.H., PAPAC, R.J., SASAKI, C., FISCHER, D.B., LAWRENCE, R., ROCKWELL, S., SARTORELLI, A C. & FISCHER, J.J. (1989). Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 17, 3-9.
69. ZEMAN, E.M. & BROWN, J.M. (1989). Pre- and post-irradiation radiosensitization by SR4233. Int. J. Rad. Oncol. Biol. Phys., 16, 967-971.
70. ZEMAN, E.M., BROWN, J.M., LEMMON, M.J., HIRST, V.K. & LEE, W.W. (1986). SR4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12, 1239-1242.
71. ZEMAN, E.M., HIRST, V.K., LEMMON, M.J. & BROWN, J.M. (1988). Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR4233. Radiother. Oncol., 12, 209-218.
72. ZWI, L.J., BAGULEY, B.C., GAVIN, J.B. & WILSON, W.R. (1989). Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). JNCI, 81, 1005-1013.